Briefing
Abstract 3845: Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical data
Median limit of detection across timepoints was 1.90 PPM (IQR 1.53-2.70) at a median cfDNA input of 12 ng. 45.3% of tests were ctDNA-positive. 40.2% of detections were below 100 PPM, and 14.7% of all detections were below 10 PPM. Among patients who became sustainably positive after a negative timepoint, 49% had a first MRD-positive result below 10 PPM. Two case examples (NSCLC and colorectal cancer) describe low-PPM detections that preceded imaging-confirmed recurrence. This is a real-world analytical and descriptive series, not a prospective outcomes trial.
- n: more than 5,000 patients across 15 cancer types, as stated in the abstract (a single exact n is not given)
- Assay: NeXT Personal Dx (Personalis), bespoke panel of up to about 1,800 variants